Georgia Lawmakers Convene to Expand Medical Cannabis Access at Mercer University

Georgia lawmakers and medical cannabis advocates gathered at Mercer University in Macon to debate broadening the state's decade-old medical cannabis program. The meeting signals a potential shift in policy that could benefit more patients amid slow progress and production limits. With over 33,000 approved patients but only three operating production facilities, advocates argue the restrictions leave many without adequate options.

Cautious Approach Guides Policy Review

Representative Mark Newton emphasized the need for thorough study before any expansion. Georgia legalized medical cannabis in 2015, yet the program remains limited to low-THC oil. Newton stated that rushing policy could undermine careful implementation after nearly ten years of operation. This study committee aims to balance evidence with access, reflecting lawmakers' wariness of unproven changes in a field still evolving nationally.

Proven Benefits Fuel Push for Change

Representative Robert Dickey highlighted real-world advantages for patients in need. He noted that limited medical research stems from cannabis's federal illegality, which has slowed scientific progress. Dickey described the committee's work as facilitating opportunities to help more Georgians. Over 10 dispensaries serve the state, but supply constraints from just three producers, including Fine Fettle in Macon, hinder distribution.

Industry Calls for Stronger Products

Judson Hill, president of Fine Fettle, urged lawmakers to raise THC percentages in approved oils. Georgia's low-THC program lags behind 40 other states with fuller medical cannabis frameworks. Hill argued that current strengths fail to meet patient needs, restricting effective treatment. This gap positions Georgia behind national trends where broader access correlates with targeted relief for conditions like chronic pain and epilepsy.

Implications for Patients and Policy

Expansion could address supply shortages and product limitations, aligning Georgia with most states offering robust medical programs. Yet lawmakers prioritize data-driven decisions to avoid overreach. Patients stand to gain from enhanced options, but federal barriers continue to limit research and interstate commerce. The Mercer discussions mark a step toward modernization, with outcomes likely to shape access for thousands more.